Clinical Trial Update: Study to Evaluate the Pharmacokinetics (PK) and Safety/Tolerability of Long-Acting Oral LYN-005 [Phase 3]

View source ↗

Summary

Phase 3 study evaluating pharmacokinetics and safety/tolerability of Long-Acting Oral LYN-005 in schizophrenia and schizoaffective disorder has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizoaffective Disorder
• Schizophrenia

Drugs mentioned

• LYN-005

Snippet

Sponsor: Lyndra Inc. | Conditions: Schizophrenia, Schizoaffective Disorder | Phase 3 | Status: COMPLETED